agilon health turned in a stronger Q1 after a brutal FY2025 reset, but the thesis still depends on whether member exits, payor discipline, ACO contribution and CEO execution can hold up against Medicare Advantage medical-cost trend.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
